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Abstract
Endocrine tumours of the gastrointestinal tract and pancreas may present at different disease stages
with either hormonal or hormone-related symptoms/syndromes, or without hormonal symptoms. They
may occur either sporadically or as part of hereditary syndromes. In the therapeutic approach to a
patient with these tumours, excessive hormonal secretion and/or its effects should always be
controlled first. Tumour-related deficiencies or disorders should also be corrected. Subsequently,
control should be aimed at the tumour growth. Surgery is generally considered as first-line therapy for
patients with localized disease, as it can be curative. However, in patients with metastatic disease the
role of first-line surgery is not clearly established and other therapies should be considered, such as
non-surgical cytoreductive therapies, biotherapy (with somatostatin analogues or interferon-a),
embolization and chemoembolization of liver metastases, chemotherapy (with single or multiple
dose regimens) and peptide receptor-targeted radiotherapy. The delicate balance of the use of the
different therapeutical options in patients with endocrine tumours of the gastrointestinal tract and
pancreas emphasizes the importance of team approach and team expertise.
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Introduction
Endocrine tumours of the gastrointestinal tract and
pancreas (Solcia et al. 2000), carcinoids of the digestive
tract and bronchi, and islet cell tumours of the pancreas
belong to a rare and heterogeneous group of tumours with
great variability in clinical behaviour.
According to their different presentations and/or
clinical manifestations, different diagnostic and therapeu-
tic approaches can be followed; these have to be
individualized between patients. In some areas there
seems to be a consensus on the choice of the diagnostic
and therapeutic approach, in other areas an individualized
approach seems best at present. We have tried to design
general as well as differential therapeutic recommenda-
tions for these tumours.
Knowledge about the natural history of endocrine
tumours of the gastrointestinal tract and pancreas is
essential in order to allow identification of prognostic
factors and subgroups of patients with different prog-
noses. These tumours may present at different disease
stages and accurate localization and staging can be
difficult. In the near future, it should be more possible
to make a more individual therapeutic approach on the
basis of predicted tumour behaviour and identify when
less or more aggressive therapy is warranted. In this
respect, studies are now looking into reliable prognostic
clinical, radiological, serum or histological markers
(Stabile 1997).
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The role of the presentation and estimates
of the degree of malignant behaviour
Functioning vs non-functioning tumours
Endocrine tumours of the gastrointestinal tract and
pancreas can be subdivided into those presenting with
hormonal or hormone-related symptoms/syndromes and
those without hormonal symptoms, the so-called ‘non-
functioning tumours’. In patients with these non-func-
tioning tumours, morbidity and mortality mainly result
from tumour expansion and spread, although these
tumours may later in their disease course start producing
biologically active hormones.
Hereditary vs non-hereditary tumours
Pancreatic islet cell tumours may occur sporadically, or
as part of the multiple endocrine neoplasia type I
(MEN-I) syndrome (Medelian Inheritance in Man
(MIM) 193300), von Hippel–Lindau syndrome (MIM
193300), neurofibromatosis type 1 (von Recklinghausen
disease) (MIM 162200) and tuberous sclerosis (MIM
191100) (Griffiths et al. 1987, Swinburn et al. 1988,
Brandi et al. 2001). As an example, it has been shown
that (metastatic) gastrinomas, either sporadic or MEN-I
associated, may follow highly variable patterns. Gen-
erally, 40–90% of MEN-I gene carriers develop pan-
creatic endocrine tumours (Calender 2000). Apart from
the complications caused by the excessive hormone
secretion by these tumours, MEN-I patients may also
suffer from complications of the hormone excess caused
by hypersecretion or tumours of other endocrine glands
such as pituitary tumours and hyperparathyroidism.
Nowadays, many of these complications can be radically
treated surgically or medically. Improved genetic,
hormonal, nuclear and radiological imaging screening
programs and successive follow-up of carriers of MEN-I
gene defects allows earlier diagnosis and treatment of de
novo tumours in these gene carriers (Brandi et al. 2001).
As a result, patients with gastrinomas and the MEN-I
syndrome tend to live longer than some years ago. The
National Institute of Health group of Jensen and co-
workers (Gibril et al. 2001) was the first to prospectively
follow a relatively large group of MEN-I-associated
gastrinomas. At a mean follow-up of 8 years, these
authors have shown that 14% of patients had aggressive
growing gastrinomas, which were associated with
decreased survival. In this study, factors predictive of
aggressive growth of gastrinoma in MEN-I patients
were: age at diagnosis of both gastrinoma and of MEN-
I, age at diagnosis of Zollinger–Ellison syndrome,
duration of Zollinger–Ellison syndrome before diagno-
sis, fasting gastrin levels, tumour size, presence of liver
metastases, presence of bone metastases and presence of
gastric carcinoids (Gibril et al. 2001).
In neurofibromatosis type 1, duodenal somatostati-
nomas may occur. The vast majority of these tumours
occur near the ampulla of Vater, where they tend to cause
obstructive jaundice at an early stage (Griffiths et al.
1987). Because of their size these tumours are generally
amenable to surgery. In contrast, even more rare sporadic
gastrinomas usually occur in the pancreas and are
diagnosed at a much later stage when features of
hyperglycaemia, steatorrhoea, cholelithiasis and diar-
rhoea or abdominal pain have occurred (Ganda et al.
1977, Krejs et al. 1979).
Parameters of malignant behaviour
Immunohistochemical markers for neuroendocrine
tumours are: chromogranin A (CgA), synaptophysin,
neurone specific enolase and protein gene product 9.5
(Oberg et al. 1999). Poorly differentiated and anaplastic
endocrine tumours of the gastrointestinal tract and
pancreas generally show no staining for CgA. In retro-
spective series, the presence of synchronous or develop-
ment of metachronous distant metastases (and rapid
progression of these metastases), loss of functionality of
the tumour, tumour size larger than 4 cm, the presence of
or development of ectopic hormone syndromes and
synchronous/metachronous OctreoScan (Tyco Health-
care/Mallinckrodt, St Louis, MO, USA) negativity have
been considered poor prognostic factors in patients with
endocrine tumours of the gastrointestinal tract and
pancreas (Kvols et al. 1992, Metz et al. 1993, Krenning
et al. 1994, Weber et al. 1995, Sutliff et al. 1997, Yu et al.
1999). In these tumours, important histological markers
of poor prognosis are: more than 2% Ki 67-positive cells,
angioinvasion/perineural invasion, more than two
mitoses/10 high power field (2mm2) and p53 overexpres-
sion (Chaudhry et al. 1992, La Rosa et al. 1996, Rindi et
al. 1999, 2000, Rigaud et al. 2001). Loss of heterozygosity
(LOH) analysis has also demonstrated high frequency of
6q and 11q LOH, but the clinical significance of these
findings is not yet clear (Rigaud et al. 2001). Apart from
the already mentioned prognostic parameters for endo-
crine tumours of the gastrointestinal tract and pancreas,
studies in patients with carcinoid tumour have identified
that sex, primary tumour site, tumour size, tumour
invasiveness, presence of the carcinoid syndrome, elevated
serum CgA levels and elevated urinary excretion of 5-
hydroxy indole acetic acid (5-HIAA), as well as aneu-
ploidy, are additional markers of poor prognosis in these
patients (Greenberg et al. 1987, McDermott et al. 1994,
Stridsberg et al. 1995, Tiensuu Janson & Oberg 1996,
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Modlin & Sandor 1997, Nobels et al. 1997, Soga 1998,
Jensen 2000).
Peptide receptors
Endocrine tumours of the gastrointestinal tract and
pancreas may produce one or several peptide hormones.
It is possible to measure the levels of most peptides in the
blood, providing suitable markers for disease stage and
endocrinological activity. In addition, the high expression
of receptors for some peptides by these tumours provides
other valuable tumour markers and allows for therapy
with receptor agonists or antagonists, diagnostic scinti-
graphy with radiolabelled analogues and therapy with
radiolabelled or cytotoxic analogues (see later) (de Herder
et al. 1996a, 2003, Hofland & Lamberts 2003, Reubi &
Waser 2003).
Somatostatin receptor-binding studies, somatostatin
mRNA determination and/or somatostatin receptor
immunohistochemistry have identified abundant expres-
sion of somatostatin receptors in endocrine tumours of
the gastrointestinal tract and pancreas (Reubi et al. 1987,
1990). In general, somatostatin receptor expression varies
between patients and between tumours. Although most
endocrine tumours of the gastrointestinal tract and
pancreas have a rather homogeneous somatostatin
receptor distribution some may show a more hetero-
geneous somatostatin receptor distribution. Complex
patterns of somatostatin receptor subtype mRNA expres-
sion have been observed (Jais et al. 1997, Schaer et al.
1997, Wulbrand et al. 1998).
Non-endocrine gastrointestinal tumours can express
the vasoactive intestinal polypeptide (VIP) receptor
subtype VPAC1 (Reubi et al. 2000). The cholecystokinin
(CCK) and gastrin receptor subtype CCK2 (CCK-B) are
expressed in some of the endocrine tumours of the
gastrointestinal tract and pancreas (in particular in
insulinomas) and the subtype CCK1 (CCK-A) receptors
can also be expressed (Reubi et al. 1997, Reubi & Waser
2003). The expression of bombesin and gastrin-releasing
peptide (GRP) receptor subtypes (neuromedin B receptor
subtype (BB1), GRP receptor subtype (BB2), BB3 and
BB4) has been studied in both endocrine and non-
endocrine tumours of the gastrointestinal tract and
pancreas. Gastrinomas preferentially express GRP recep-
tors and ileal carcinoids often express neuromedin B
receptors (Reubi et al. 2002, Reubi & Waser 2003).
Ongoing studies are examining the expression of neuro-
tensin receptors (such as the receptor subtype NRT1),
substance P (such as the receptor subtype NK1),
neuropeptide Y and other peptides in endocrine tumours
of the gastrointestinal tract and pancreas (Reubi & Waser
2003).
Treatment objectives
Hormonal control
In the stepwise therapeutic approach to a patient with an
endocrine tumour of the gastrointestinal tract and
pancreas, excessive hormonal secretion and/or its effects
should always be controlled first. This includes the
following.
Islet cell tumours of the pancreas
. Control of gastric acid hypersecretion and its effects in
patients with the Zollinger–Ellison syndrome using high
doses of proton pump inhibitors, frequent administra-
tion of high doses of histamine H2-receptor antagonists
and/or somatostatin analogues. Nowadays, total gas-
trectomy and parietal cell vagotomy are almost
obsolete (Jensen 1996).
. Control of hypoglycaemia in patients with insulinomas
by administering frequent meals, and/or continuous or
overnight glucose infusions and/or diazoxide therapy
(Service 1993).
. Control of hyperglycaemia in patients with glucagono-
mas and somatostatinomas using insulin or oral blood
glucose-lowering drugs, or somatostatin analogues
(Krejs et al. 1979, Bloom & Polak 1987, Lamberts et
al. 1996).
Islet cell tumours of the pancreas and carcinoids
. Control of diarrhoea and/or flushing in patients with
the carcinoid syndrome or VIPoma by somatostatin
analogues and loperamide or ondansetron (Stabile
1997, Caplin et al. 1998, Wymenga et al. 1998, Kulke
& Mayer 1999).
. Control of Cushing’s syndrome in patients with ectopic
adrenocorticotrophin production by (combinations of)
somatostatin analogues, ketoconazole, metyrapone,
etomidate, or by laparoscopic biadrenalectomy (Lam-
berts et al. 1994, Wajchenberg et al. 1994, de Herder &
Lamberts 1996, 1999).
. Control of acromegaly in patients with ectopic growth
hormone-releasing hormone production by somatosta-
tin analogues (Von Werder et al. 1984, Lefebvre et al.
1995, Drange & Melmed 1998, Doga et al. 2001).
. Control of humoural hypercalcaemia of malignancy in
patients with paraneoplastic parathyroid hormone-
related peptide production by somatostatin analogues
(Wynick et al. 1990, Mantzoros et al. 1997, Barhoum
et al. 1999).
Carcinoids
Carcinoids of the small intestine (previously designated as
midgut carcinoids) are the most common carcinoids.
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After metastasizing to the liver, bioactive amines may
reach the systemic circulation and the carcinoid syndrome
ensues. These small intestinal carcinoids account for 75-
90% of all case of the carcinoid syndrome (Oberg 1997,
Jensen 1999). In the case of the carcinoid syndrome,
somatostatin analogue therapy (using s.c. octreotide
(Sandostatin; Novartis Pharma, Basle, Switzerland), i.m.
Sandostatin LAR (Novartis Pharma), s.c. lanreotide
(Somatuline; Beaufour Ipsen, Paris, France), i.m. lanreo-
tide-PR (Somatuline-PR; Beaufour Ipsen) or s.c. Lanreo-
tide Autogel (Beaufour Ipsen)) results in complete
disappearance of flushing episodes in approximately
60% of patients, while in more than 85% the frequency
and/or severity of the flushing periods can be reduced to
less than 50%. Disappearance of diarrhoea is observed in
more than 30%, and there is a more than 50%
improvement in more than 75% of patients with this
therapy. Biochemically, a significant reduction of the
increased urinary excretion of 5-HIAA in more than 50%
of patients has been found (Kvols et al. 1986, Kvols 1989,
Oberg 1997, Caplin et al. 1998, Kulke & Mayer 1999).
Also, objective transient anti-neoplastic effects have been
reported with this therapy (see later). However, insensi-
tivity (tachyphylaxis) to somatostatin analogues may
develop in time (de Herder et al. 1996a).
Correction of tumour-related deficiencies or
disorders
Apart from therapies directly targeted at the tumour/
tumour syndromes, tumour-related deficiencies and dis-
orders should also be taken care of. This involves the
following.
. Supplementation of nicotinic acid in patients with
carcinoid syndrome and nicotinic acid deficiency
(Swain et al. 1976).
. Topical or oral zinc therapy to ameliorate the necrolytic
migratory erythema in patients with glucagonoma
(Burton 1993, Chastain 2001).
. Aspirin therapy for the prevention of thrombo-embolic
disease in patients with glucagonoma (Chastain 2001).
. Resection of mesenterial fibrosis and heart valve
replacement in patients with carcinoid syndrome and
carcinoid heart disease (Ahlman 1996, Westberg et al.
2001, Quaedvlieg et al. 2002, Moller et al. 2003).
Carcinoid heart disease, eventually leading to right-sided
heart failure, is an important cause of death in patients
with the carcinoid syndrome. In this disorder, plaques are
deposited on the endocardium, leading to tricuspid valve
insufficiency and pulmonary valve stenosis. In close
collaboration with cardiologists and thoracic surgeons,
protocols have been developed that include extensive
cardiologic monitoring of patients with the carcinoid
syndrome, in whom surgical and/or medical therapy has
reduced the effects of hormonal hypersecretion. This will
eventually lead to a careful selection of patients and
correct timing of valve replacement before end-stage heart
failure develops (Connolly et al. 1995, Westberg et al.
2001, Quaedvlieg et al. 2002, Moller et al. 2003).
Control of tumour growth
The second stage of the therapeutical work-up of a patient
with an endocrine tumour of the gastrointestinal tract and
pancreas is control of tumour growth. The sensitivity and
specificity of the different imaging modalities for diagno-
sing and localizing primary endocrine tumours of the
gastrointestinal tract and pancreas and their possible
metastatic spread will not be extensively discussed in this
paper (see Ricke et al. 2001). It is, however, obvious that
meticulous localization is mandatory for the patient’s
work-up for therapy. Are we dealing with a patient with
localized disease or metastatic disease? Again, knowledge
of the natural history of the tumour is very essential. Less
than 10% of insulinomas show malignant behaviour,
whereas 60–90% of gastrinomas and 40–70% of VIPomas
are malignant (Stabile 1997, Jensen 1999). Somatostatin
receptor imaging (using OctreoScan) is currently con-
sidered to be the first-line imaging modality for the
staging of patients with the Zollinger–Ellison syndrome
(Gibril et al. 1996, Termanini et al. 1997, Alexander et al.
1998). Five-year survival for gastrinoma patients with
liver metastases is low and varies between 40 and 75%,
whereas it is almost 100% when no liver metastases are
present (Weber et al. 1995, Sutliff et al. 1997, Madeira
et al. 1998, Wiedenmann et al. 1998, Yu et al. 1999).
Surgery
Surgery is generally considered as first-line therapy for
patients with localized disease, as it can be curative
(Doherty et al. 1991, Norton 1994, Wiedenmann et al.
1998, Norton et al. 1999). However, in patients with
metastatic disease the role of first-line surgery is not
clearly established. In patients with metastatic carcinoids
with liver and mesenteric metastases, conservative
resections of the intestine, mesenteric tumours and
fibrotic areas may considerably improve symptoms and
quality of life (Makridis et al. 1990, 1996, 1997,
Sarmiento et al. 2003). Whether the reduction of tumour
mass by surgical intervention enhances a favourable
outcome for future medical treatment has not, however,
been established (Gulec et al. 2002). The extent of a
surgical resection should be well-balanced against
morbidity and the role of medical and other therapies
to control symptoms (Wiedenmann et al. 1998). Indeed,
patients with liver metastases from endocrine tumours of
the gastrointestinal tract and pancreas have a significant
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decrease in survival as compared with patients with
localized tumours with or without lymph node metas-
tases (Modlin & Sandor 1997). Studies have also
demonstrated that in the case of a gastrinoma, surgical
removal of the primary tumour decreases the probability
that liver metastases will develop. In the case of a
limited number and extent of liver metastases, metas-
tatectomy should, therefore, be considered (Ahlman et al.
1996, Jaeck et al. 2001, Goering et al. 2002, Sarmiento
et al. 2003). However, liver metastases are often multiple
and diffuse throughout the liver parenchyma, thus
precluding resection in more than 90% of patients
(McEntee et al. 1990).
The different clinical behaviour and prognosis of
pancreatic islet cell tumours in the presence or absence of
the MEN-I syndrome have been elegantly demonstrated
for gastrinomas. Approximately 20–25% of gastrinoma
patients have the MEN-I syndrome. MEN-I-associated
gastrinomas usually present at an earlier age. Most MEN-
I patients have coexisting hyperparathyroidism or
pituitary disease at the time of presentation of the
gastrinoma. Also, (generally multifocal) gastric carcinoid
tumours from the enterochromaffin-like cells (so-called
‘ECLomas’) are more frequently found in patients with
MEN-I-associated gastrinoma (15–30% of cases) than in
sporadic gastrinomas (<5%). This implies that the
therapeutic approach to endocrine tumours of the
gastrointestinal tract and pancreas may differ between
patients with and without the MEN-I syndrome (Jensen
1996, 1998, Norton et al. 1999).
Liver transplantation
A limited number of liver transplantations have been
performed in patients with either absent or resectable
extrahepatic spread of endocrine tumours of the gastro-
intestinal tract and pancreas, which could then be
completely resected with curative intent. The exact role
and especially the exact timing of this procedure needs to
be further defined. Early experiences have been obtained
in patients who were generally younger than 55 years with
a hepatic tumour mass involving less than 50% of total
liver volume. These patients had either previously under-
gone curative metastatectomies or liver resections with
curative intent, or had demonstrated progression of liver
metastases after hepatic artery embolization. In a few
patients, the indication for liver transplantation was
uncontrollable life-threatening hormone production by
non-anaplastic endocrine tumours of the gastrointestinal
tract and pancreas (as in the case of metastatic VIPoma
and metastatic insulinoma) (Dousset et al. 1996, Lehnert
1998, Ahlman et al. 2000, Olausson et al. 2002, Cahlin
et al. 2003).
Non-surgical cytoreductive therapies
Biotherapy
On the basis of in vitro studies demonstrating anti-
proliferative and apoptotic effects of somatostatin analo-
gues, uncontrolled prospective studies using standard
doses of s.c. octreotide (Sandostatin), i.m. Sandostatin
LAR, s.c. lanreotide (Somatuline), i.m. lanreotide-PR
(Somatuline-PR) or s.c. lanreotide autogel have been
designed in patients with progressive endocrine tumours
of the gastrointestinal tract and pancreas (Imam et al.
1997). However, only limited numbers of patients have
been studied. Anaplastic tumours were excluded from
most studies. Stable disease lasting for a minimum of 3
months and a maximum of 5 years was attained in 20–
70% of patients and a partial response only in less than
6% of patients (Saltz et al. 1993, Arnold et al. 1996, Di
Bartolomeo et al. 1996, Ruszniewski et al. 1996,
Wymenga et al. 1999, Ducreux et al. 2000, Aparicio et
al. 2001, Shojamanesh et al. 2002, de Herder et al. 2003).
Preliminary studies have shown that ultra-high doses of
the currently available somatostatin analogues may cause
tumour shrinkage in selected patients (Faiss et al. 1996,
Eriksson et al. 1997). Therapy with interferon-a (either 2a
or 2b) also causes a biochemical response in 44% (25–
71%) of patients and a tumour response in 11% (0–27%)
of patients with tumours with a low proliferative index
(i.e. less than 2% Ki 67-positive cells) (Oberg 1997, 2000,
Faiss et al. 2003). Synergistic effects with combination
therapy of somatostatin analogues with interferon-a have
been reported and prospective trials have been designed to
confirm these results (Joensuu et al. 1992, Janson & Oberg
1993, de Herder et al. 1996b, Lamberts et al. 1996, Frank
et al. 1999, Oberg 2001, Fjallskog et al. 2002, Faiss et al.
2003).
Chemotherapy
To date, no single-agent or combination chemotherapy
trial has demonstrated a significant beneficial effect in
patients with well-differentiated endocrine tumours of the
gastrointestinal tract (such as carcinoids) and pancreas. In
contrast, chemotherapy may have important beneficial
effects in selected patients with aggressive poorly differ-
entiated tumours (grade 3 according to World Health
Organization criteria (Solcia et al. 2000)). These tumours
display an aggressive behaviour that is similar to small cell
lung cancer. With combinations of streptozotocin and
either 5-fluorouracil or doxorubicin, objective response
rates up to 67% have been achieved in undifferentiated
islet cell tumours (Chernicoff et al. 1979, Moertel et al.
1980, 1992, Bukowski et al. 1987, Eriksson et al. 1990,
Rougier et al. 1991, Rivera & Ajani 1998, Rougier &
Mitry 2000). Combination chemotherapy of fast-growing
anaplastic neuroendocrine carcinomas with etoposide and
Endocrine-Related Cancer (2004) 11 19–34
www.endocrinology.org 23
cisplatin resulted in objective responses in up to 41% of
patients (Mitry et al. 1999). These chemotherapy sche-
dules all had considerable side-effects and, despite the
chemosensitivity of these tumours, their prognosis
remains very poor with a short duration of response (up
to a maximum median survival of 2 years) (Moertel 1987,
Moertel et al. 1991, Rougier & Mitry 2000).
Embolization and chemoembolization
In patients with significant (generally more than 50%) liver
involvement by diffuse metastases of carcinoids, sequential
selective hepatic artery embolization can result in objective
tumour responses and a transient but significant reduction
of hormone secretion. Higher response rates might be
obtained by combining hepatic artery embolization with
systemic chemotherapy or by chemoembolization. The
latter procedure has the advantage of achieving higher
intrahepatic intratumoural concentrations of the cytotoxic
drugs in combination with decreased hepatic clearance and
local ischaemia. These procedures can generally be
repeated every 4–6 weeks to a maximum of three
procedures, as the effect then decreases because of the
development of collateral blood supply to the liver. In
patients eligible for these therapies, extrahepatic spread
should be less extensive than the hepatic spread. Complete
portal vein thrombosis, hepatic failure (i.e. proaccelerin
level <50%) and previous Whipple’s procedure (which
increases the risk of biliary ischaemia with biliary sepsis)
are contra-indications. Generally, the procedures are
carried out under general anaesthesia and under the
cover of somatostatin analogues. The effects of (chemo-)
embolization on symptomatic control of the carcinoid
syndrome are encouraging: more than 50% decrease of
urinary 5-HIAA excretion was achieved in 50–100% of
patients and tumour progression was inhibited for a period
of 0.5–3.5 years in 30–80% (Ruszniewski & Malka 2000).
Another clinical indication for this type of therapy is
uncontrollable hypoglycaemia caused by diffuse liver
metastases of malignant insulinoma (Ruszniewski et al.
1993, Perry et al. 1994, Wangberg et al. 1996). Other
therapies directed to reduce the number and size of liver
metastases are: (percutaneous) ethanol injection, cryoabla-
tion and radiofrequency (Chung et al. 2001a, Jaeck et al.
2001, Siperstein & Berber 2001, Berber et al. 2002, Choy et
al. 2002, Goering et al. 2002, Sheen et al. 2002). However,
good prospective trials on these therapies are presently
lacking.
Peptide receptor-targeted radiotherapy
123I- and 131I-meta-iodobenzylguanidine (MIBG) may
accumulate in digestive endocrine tumour cells. Scinti-
graphy with this radiopharmacon demonstrates metabolic
active tumours and metastases in more than 60% of
patients with endocrine tumours of the gastrointestinal
tract and pancreas. This technique can also be used for the
selection of patients for therapy with non-radioactive
MIBG or 131I-MIBG (Taal et al. 1996).
Somatostatin receptor-mediated endocytosis is of
particular importance when radiotherapy or chemother-
apy of somatostatin receptor subtype (sst)2- and sst5-
positive metastatic carcinoids and pancreatic neuroendo-
crine tumours with a- or b-emitting radionuclides or
chemotherapeuticals coupled to somatostatin analogues
are considered (Hofland et al. 1999). The process of
internalization might bring the radioligand or cytotoxic
somatostatin analogue closer to the nucleus and its DNA
(Janson et al. 2000). A high, selective uptake of radio-
activity or the chemotherapeutical is necessary, as non-
neoplastic tissues expressing somatostatin receptors
should not be exposed to the toxic effects of the
radioligand or cytotoxic analogue. [111In-DTPA0,
D-Phe1]octreotide (111In-pentetreotide) emits both Auger
electrons (which have a tissue penetration of only 0.02–
10mm) as well as conversion electrons, with a tissue
penetration of 200–500 mm. High doses of 111In-pente-
treotide inhibited growth of sst2-positive tumour cells in
vitro (Slooter et al. 1999). It has also been shown that
111In-pentetreotide can inhibit the growth of liver
metastases after injection of sst2-positive tumour cells
into the portal vein of rats (Slooter et al. 1999). In patients
with progressive metastatic neuroendocrine tumours,
therapy with 111In-pentetreotide (performed in three
centres, n=81 patients) resulted in a partial response in
7% of patients, a minor response in 7%, 57% of patients
had stable disease and progressive disease was observed in
28% (McCarthy et al. 1998, 2000, de Jong et al. 1999,
Krenning et al. 1999, Tiensuu et al. 1999, Caplin et al.
2000, Anthony et al. 2002, Valkema et al. 2002). Therapy
with somatostatin analogues coupled to b-emitting radio-
nuclides, such as 90Y and 177Lu, is potentially more
effective, as higher tumour radiation doses can be
achieved and the longer range of the b-particles (1–
10 mm) may also lead to radiation of neighbouring
receptor-negative tumour cells (so-called ‘cross-fire’).
Therapy of patients with endocrine tumours of the
digestive tract and pancreas with [90Y-DOTA0,Tyr3]oc-
treotide (90Y-DOTATOC or 90Y-SMT487/OctreoTher;
Novartis Pharma) has resulted in partial responses
(including a few complete responses) in 18%, minor
responses in 11%, 53% of patients had stable disease and
progressive disease was observed in 17% (based on phase
I/II data obtained in more than 100 patients) (Otte et al.
1998, 1999, Paganelli et al. 1999, 2001, Smith et al. 2000,
Waldherr et al. 2001). Therapy with [177Lu-DOTA0,Tyr3]-
octreotate in 34 patients with endocrine tumours of the
gastrointestinal tract and pancreas have shown partial
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remission in 38% of patients (including one case with
complete remission), 41% of patients had stable disease
and 21% of patients had progressive disease (Kwekke-
boom et al. 2001, 2003) (Fig. 1). Furthermore, [111In-
DOTA0]lanreotide and [90Y-DOTA0]lanreotide can also
be used for radiotherapy of sst2- and sst5-positive
advanced, or metastatic endocrine tumours (Virgolini et
al. 2002).
Several mechanisms may determine the amount of
uptake of radiolabelled somatostatin analogues. These
include: (1) the stability of the radioligand, (2) the density
of sst expression on the tumour, (3) the type of ssts
expressed by the tumour, (4) affinity of the radioligand for
the sst, (5) the efficiency of sst-mediated internalization
and recycling, (6) the final trapping of the radioisotopes
within the tumour cells, as well as (7) the mass of the
injected peptide (Nouel et al. 1997, Hukovic et al. 1999,
Hofland & Lamberts 2003). The longer particle range of
b-emitting radionuclides is an advantage for median to
larger tumour lesions. In micrometastases, however, the
absorbed fraction of the radiation energy in the tumour
cells will be very low. In these small lesions, therapy with
Auger electron and a-particles emitting radiopharmaceu-
ticals may be a better choice. These observations open the
perspective of treating future patients with cocktails of
radionuclides, irradiating larger lesions with b-emitting
radiolabelled peptides and microscopic lesions with Auger
or a-particle-emitting peptides. It is also conceivable to
use 111In-pentetreotide as neo-adjuvant therapy in
patients with sst2-positive tumours operated with curative
intent to treat occult (micro)metastases. Major toxicities
observed in trials with peptide receptor-targeted radio-
therapy were the development of myelodysplastic syn-
drome and/or acute myeloid leukaemia in four patients,
three in a phase I study with 111In-pentetreotide and one
in a phase I study with [90Y-DOTA0,Tyr3]octreotide and
delayed renal insufficiency in a phase I study with [90Y-
DOTA0,Tyr3]octreotide without kidney protection with
amino acids (Cybulla et al. 2001, Valkema et al. 2002).
Furthermore, decline in platelets was generally mild and
transient, leucocytopenia was without clinical implica-
tions, but there is evidence for impaired spermatogenesis
with 111In-, 90Y- and 177Lu-labelled octreotide treatment
based on a decline in serum inhibin B and an increase in
serum follicle-stimulating hormone levels (Valkema et al.
2002). It is evident that with increasing tumour uptake, as
for instance shown by 111In-pentetreotide scintigraphy
(OctreoScan), the results of these therapies are more
impressive and patients with OctreoScan-negative tumour
deposits will not benefit.
Chelated and non-chelated octapeptide somatostatin
analogues have also been attached to various cytotoxic
compounds (Plonowski et al. 1999, 2000, 2001, 2002,
Benali et al. 2000, Kiaris et al. 2001, Szepeshazi et al.
2001, 2002). Using the currently available analogues,
somatostatin receptor-targeted chemotherapy may also
prove to be only effective in sst2- and sst5-positive
tumours (Kwekkeboom et al. 1999, Smith et al. 2001).
Therapy studies with radiolabelled and non-radiolabelled
somatostatin analogues linked with cytotoxic compounds
Figure 1 A 31-year old woman with metastatic gastrinoma treated with four courses of [177Lu-DOTA0,Tyr3]-octreotate, cumulative
dose 29.8 GBq. T1-weighted images with fat suppression after the administration of Gd-DTPA, arterial phase. a, baseline studies; b,
studies performed after 7 months. Studies show a significant reduction of both the cystic and solid part of the liver metastases,
classified as a partial response.
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have so far been carried out in experimental tumour
models only and are very promising. External beam
radiation may be of benefit in patients with progressing
bone metastases close to the central nervous system.
Towards individualized therapeutic advice
Disease-independent variables
It is important to realize that patient-dependent and
disease-independent variables may also have an effect on
the choice of treatment of endocrine tumours of the
gastrointestinal tract and pancreas, variables such as the
local availability of drugs or techniques, local expertise,
the patient’s preference and costs of health care systems/
insurance companies. Also, accompanying medical con-
ditions that can significantly shorten the patient’s life
expectancy should be taken into account.
Multidisciplinary team advice
The delicate balance of the use of the different therapeu-
tical options in patients with endocrine tumours of the
gastrointestinal tract and pancreas emphasizes the impor-
tance of team approach and team expertise (Fig. 2). The
experts participating in such a team could be endocrinol-
ogists, gastroenterologists, surgeons, pathologists, radio-
therapist experienced in neuroendocrine problems,
oncologists and physicians with knowledge of nuclear
medicine.
Future developments and questions
It seems evident that therapeutic strategies for the
various subgroups of endocrine tumours of the gastro-
intestinal tract and pancreas may dramatically change in
the near future with the introduction of new therapies.
Somatostatin binds with high affinity to all ssts (sst1–5),
whereas the octapeptide analogues octreotide and
lanreotide only bind with a high affinity to sst2 and
sst5 (Patel 1999). New classes of sst-selective analogues
are being developed and tested. As every somatostatin
receptor has distinct biological functions, these new
analogues may prove valuable for the treatment of
tumours that are already sensitive to the currently
available octapeptide analogues, but also for tumours
that express other ssts than sst2 and sst5. A new so-
called ‘universal’ somatostatin analogue, named
SOM230, with high affinity for sst1, sst2, sst3 and sst5
is currently under evaluation in phase I–III trials
(Lamberts et al. 2002, Bruns et al. 2002, Weckbecker
et al. 2002). New drugs interacting with multi-receptor
family cross-talk are being developed. These sst subtype
homo- or heterodimers may have properties which are
distinct from the individual receptors in terms of
internalization, agonist-induced desensitization and func-
tional activity (Rocheville et al. 2000a,b, Pfeiffer et al.
2001, 2002).
Powerful b-emitting radionuclides coupled to these
somatostatin analogues will potentially increase the
therapeutic potential of peptide receptor-targeted radio-
therapy for metastatic somatostatin receptor-positive
tumours. Also, as already eluded to, the concept of
radiolabelled and non-radiolabelled somatostatin analo-
gues coupled to cytotoxic drugs is interesting and
challenging. Transfer of genes that encode for the
expression of sst2 and sst5 to receptor-negative cancers
may render these tumours responsive to these radio-
labelled or cytotoxic somatostatin analogues (Smith et
al. 2000, Benali et al. 2000, Jenkins et al. 2001).
Somatostatin immunotherapy is another future treat-
ment option for somatostatin receptor-positive tumours.
As neuroendocrine tumours are generally highly vascu-
larized, anti-angiogenesis agents may prove to be of
value in future treatment regiments as well (Drevs et al.
2002).
Many questions still have to be solved in the near
future. The most pressing ones should be studied in
clinical trials aiming to answer the following.
. How do we identify patients with endocrine tumours of
the digestive tract and pancreas who, after diagnosis,
follow a very aggressive and malignant course and how
do we address these tumours in these patients?
. What is or will still be the place for debulking surgery
and what is the likelihood of cure after repeat surgery,
especially when newer therapies (newer somatostatin
analogues and/or peptide receptor-targeted radiother-
apy) become widely available? Do both procedures
prolong survival and improve quality of life?
. Does liver transplantation in a selected group of
patients prolong survival and improve quality of life?
What patient selection and work-up is then needed?
Does neo-adjuvant peptide receptor-targeted radio-
therapy prevent or delay regrowth of metastases in
the transplanted liver?
. Is there still a place for new chemotherapeuticals and
anti-angiogenesis agents, or new trials with presently
available chemotherapeuticals?
. How can we prevent or suspend tachyphylaxis for the
currently available somatostatin analogues and how do
we handle this problem, once it has occurred? Do newer
somatostatin analogues overcome this problem and is
there a need for new and more receptor-specific
somatostatin analogues?
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. How can we prolong survival and improve quality of
life of patients with anaplastic or dedifferentiated
endocrine tumours of the digestive tract and pancreas.
. How can we improve the clinical work-up and care for
MEN-I patients with endocrine tumours of the gastro-
intestinal tract and pancreas?
. What is the role of the currently available or the newer
somatostatin analogues in clinically non-functioning
neuroendocrine tumours?
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